Rep. Kevin Hern has placed six separate trades in BSX, the highest count for any named ticker in fresh congressional filings tied to the earnings calendar. Boston Scientific is scheduled to report Q3 2026 results before the market open on October 28, with consensus estimates calling for EPS between $0.77 and $0.81 and revenue near $5.23 billion. The Oklahoma Republican also recorded five trades in HD, which faces its fiscal Q3 release on November 17 with analysts targeting EPS around $3.90 on roughly $43 billion in sales. Four trades each in DVN and OKE round out his energy exposure, while AAPL draws filings from both Hern and Rep. Pete Sessions. The pattern shows one lawmaker building a multi-sector book precisely as these companies prepare to release numbers that could move their shares. BSX carries a Strong Buy analyst consensus and has beaten estimates in recent quarters, including Q2 actual EPS of $0.86 versus $0.83 expected. Market chatter on X highlights the stock trading at 18 times earnings, its lowest P/E since 2020, with some technical accounts flagging support levels ahead of the print. HD, meanwhile, typically reports before the open on Tuesdays and posted a solid beat in its prior quarter. These filings arrive as the broader earnings watch lists 27 additional trades spread across politicians including Ro Khanna, Scott H. Peters, Richard Blumenthal and Max Miller. While the data does not disclose direction for every position, the volume and timing create a notable cluster around healthcare, consumer cyclical, energy and technology names that report between late October and mid-November. Congressional trading calendars have repeatedly shown overlap with corporate earnings windows, sometimes preceding outsized moves once results are public. With BSX guidance having seen some downward revisions earlier this year, the coming print will test whether recent product momentum in areas such as structural heart and electrophysiology can reaccelerate growth. Hern's activity across BSX, HD, DVN and OKE positions him for outcomes across both defensive healthcare and cyclical sectors at a moment when estimates remain in flux. Investors will watch whether the lawmakers' disclosed holdings benefit from beats or suffer from any softening commentary on the macro environment. This is data analysis, not financial advice.
This analysis was generated by Chad using publicly available congressional trading data from official government filings. This is not financial advice. All data is sourced from senate.gov, clerk.house.gov, and SEC EDGAR.